ManagedCareCGM

This site is intended for managed care professionals in the U.S.

This site is intended for managed care professionals in the U.S.

Professionals in Canada should visit CanadaCGM.com

Continuous Glucose Monitoring

Education for Managed Care, Pharmacy, and Payer Professionals

Featured Resources

Search
Generic filters

ADA 2022: Spotlight on Real-World Evidence Supporting the Use of Real-Time Continuous Glucose Monitoring

Recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions, where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.

Click Here to Download the Highlights


A CGM Expert Interview With Thomas Grace, MD

In a video interview, Dr. Thomas Grace, Medical Director at the Blanchard Valley Diabetes Center in Findlay, Ohio, describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in his clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.

Short on time? Click here for an abbreviated version.


Latest Research in Diabetes Technology: Highlights from ATTD 2022

Latest Research in Diabetes Technology: Highlights from ATTD 2022

Recap of real-time continuous glucose monitoring (rtCGM) abstracts from the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) – where innovation in diabetes medicines and treatments, cutting-edge technologies, and the latest research is presented. These abstracts are pertinent to managed care and payer decision makers and help characterize the value of rtCGM in improving clinical outcomes, decreasing avoidable healthcare utilization, and decreasing the burden of diabetes care management.

Click Here to Download the Highlights


A CGM Expert Interview With Davida F. Kruger, MSN, APN-BC, BC-ADM

As part of a new series of video resources hosted on ManagedCareCGM.com, Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP), offers her insights on progressive approaches to diabetes coverage and management. She shares HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level and enhanced access among patients with diabetes who are prescribed any insulin or ≥3 non-insulin medications. Findings from the MOBILE study—on which Ms. Kruger served as an investigator/author—are also detailed, including the benefits associated with real-time CGM (rtCGM) in type 2 diabetes (T2D) for improving glycemic control and meeting quality measures; these findings were particularly noteworthy considering a racially and ethnically diverse study population representing traditionally underserved demographics of patients. A post hoc analysis from MOBILE is likewise discussed, along with its implications for using rtCGM to improve T2D management among Medicare beneficiaries.

Short on time? Click here for an abbreviated version.


Video Resource: ADA Standards of Medical Care: Recommendations for Continuous Glucose Monitoring

The American Diabetes Association (ADA) Standards of Medical Care represent the latest evidence-based recommendations for guiding clinical practice. According to the most recent edition of these guidelines, Level A evidence from the MOBILE study supports the use of real time continuous glucose monitoring (rtCGM) in patients with insulin-treated type 2 diabetes (T2D) regardless of regimen. The findings from the MOBILE study likewise demonstrate the value of rtCGM across typically underserved demographics of patients impacted by social determinants of health (SDOH). Taking the ADA recommendations into consideration, payers are formulating coverage policies that facilitate appropriate access to rtCGM, improved outcomes in T2D, and proven per-member-per-month (PMPM) cost savings. 

 


Emerging Landscape of Continuous Glucose Monitoring

Source: Diabetes Technology & Therapeutics

Published: September 2021


Lower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring

Released: September, 2021

 

 

Click here to view the infographic

 


Optimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring

Released: June, 2021

 

Click here to view the infographic


Improving Quality Metrics and Reducing Cost of Care with Access to Real-Time Continuous Glucose Monitoring

Source: Improving Quality Metrics and Reducing Cost of Care with Access to Real-Time Continuous Glucose Monitoringa symposium at the Academy of Managed Care Pharmacy 2021 Virtual Annual Meeting.

Featuring expert faculty:

Jeffrey Dunn, PharmD, MBA
Head of Clinical Pharmacy
Berkshire Hathaway/Geico
(Formerly) Vice President, Clinical Strategy and Programs and Industry Relations
Magellan Rx Management

Maria Lopes, MD, MS
Former Chief Medical Officer
Magellan Health
Former Practicing Obstetrician and Gynecologist

Janet B. McGill, MD, MA, FACE, FACP
Professor of Medicine
Washington University School of Medicine

Vanita Pindolia, PharmD, BCPS, MBA
Vice President, Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System/Health Alliance Plan of Michigan

Key Takeaways: 

  • All insulin treated members,  particularly high-risk older adults, should have streamlined access to real-time CGM, and payers should reconsider coverage criteria, such as removing intensive insulin eligibility criteria for T2D and streamlining the documentation requirements.
  • Pharmacy coverage and access for appropriate subpopulations can confer immediate cost savings.
  • Consensus guidelines recommend the use of rtCGM in pregnant women with pre-existing T1 and T2D and GDM. A delay in access to CGM can have adverse consequences in terms of both maternal and neonatal outcomes.
  • rtCGM allows for a new frontier of diabetes management through remote monitoring and innovative patient engagement in telemedicine initiatives.

Jointly provided by Impact Education, LLC, and Medical Education Resources.
This activity is supported by an independent educational grant from Dexcom, Inc.


PHP Code Snippets Powered By : XYZScripts.com